Harbinger Health, SCRI to partner on clinical study

2022 06 29 19 04 8709 Scientist Record Chart Microscope Clinical 400

Biotechnology firm Harbinger Health and Sarah Cannon Research Institute (SCRI) plan to collaborate on a 10,000-participant clinical study to validate Harbinger's blood-based early cancer detection technology.

The study, called Cancer ORigin Epigenetics- Harbinger Health (CORE-HH), will enroll participants at up to 40 U.S. facilities; enrollment has begun at sites affiliated with HCA Healthcare, which is SCRI's parent company.

The initiative will run through 2023, according to the two organizations.

Page 1 of 1